Literature DB >> 28597587

The role of skin ulceration in breast carcinoma staging and outcome.

Thaer Khoury1, Carmelo Gaudioso1, Yisheng V Fang2, Souzan Sanati3, Mateusz Opyrchal4, Mohamed M Desouki5, Rouzan G Karabakhtsian6, Zaibo Li7, Dan Wang8, Li Yan8, Rebecca Jacobson9.   

Abstract

Breast carcinoma with skin ulceration (SU) is considered a locally advanced disease. The purpose of the study is to investigate if SU is an independent adverse factor. Breast carcinoma patients with SU (n=111) were included in the study. A subset (n=38, study cohort) was matched with cases that had no SU (n=38, matched cohort); the survival analyses were compared between these groups. Then, cases (n=80) were staged independent from SU into stage I, II or III. Disease free survival (DFS) and overall survival (OS) were analyzed. Patients with larger tumors tended to present with distant metastases more often than patients with smaller tumors (P=.004). In the matched cases, the 5-year DFS probability was 53% for the study cohort and 58% for the matched cohort; and for OS 75% for the study cohort and 84% for the matched cohort with no statistical significant difference. However, there was a trend towards worse DFS for the patients whose tumors had SU. When the cases were staged based on tumor size and node status (I, II or III), the OS was statistically significant (P=.047) but not the DFS (P=.195). Relatively small tumors with SU had an extent of disease similar to that observed in patients with early stages disease. The survival analysis suggests that SU may not be an adverse factor. However, more cases are needed to further examine this finding.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast carcinoma; skin ulceration; staging; survival

Mesh:

Year:  2017        PMID: 28597587      PMCID: PMC5722717          DOI: 10.1111/tbj.12830

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  13 in total

1.  CARCINOMA OF THE BREAST: II. CRITERIA OF OPERABILITY.

Authors:  C D Haagensen; A P Stout
Journal:  Ann Surg       Date:  1943-11       Impact factor: 12.969

2.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Authors:  Sara M Tolaney; William T Barry; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Matthew Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth A Overmoyer; Ann H Partridge; Hao Guo; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  N Engl J Med       Date:  2015-01-08       Impact factor: 91.245

3.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

4.  Breast carcinoma with noninflammatory skin involvement (T4b): time to abandon an historic relic from the TNM classification.

Authors:  Uwe Guth; Edward Wight; Andreas Schotzau; Igor Langer; Holger Dieterich; Christoph Rochlitz; Linda Herberich; Wolfgang Holzgreve; Gad Singer
Journal:  Cancer       Date:  2005-11-01       Impact factor: 6.860

5.  A new approach in breast cancer with non-inflammatory skin involvement.

Authors:  Uwe Güth; Edward Wight; Andreas Schötzau; Igor Langer; Holger Dieterich; Christoph Rochlitz; Linda Herberich; Wolfgang Holzgreve; Gad Singer
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

Review 6.  Scope and significance of non-uniform classification practices in breast cancer with non-inflammatory skin involvement: a clinicopathologic study and an international survey.

Authors:  U Güth; G Singer; A Schötzau; I Langer; H Dieterich; C Rochlitz; L Herberich; W Holzgreve; E Wight
Journal:  Ann Oncol       Date:  2005-07-20       Impact factor: 32.976

7.  Noninflammatory breast carcinoma with skin involvement.

Authors:  Uwe Güth; Holger Moch; Linda Herberich; Wolfgang Holzgreve
Journal:  Cancer       Date:  2004-02-01       Impact factor: 6.860

Review 8.  T4 breast cancer under closer inspection: a case for revision of the TNM classification.

Authors:  Uwe Güth; Dorothy Jane Huang; Wolfgang Holzgreve; Edward Wight; Gad Singer
Journal:  Breast       Date:  2007-07-02       Impact factor: 4.380

9.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

10.  Small size T4 breast cancer. Natural history and prognosis.

Authors:  R Zucali; R Kenda
Journal:  Tumori       Date:  1981 May-Jun
View more
  1 in total

1.  The clinical significance of metastatic breast carcinoma to intramammary lymph node.

Authors:  Thaer Khoury; Yisheng Fang; Rouzan Karabakhtsian; Mohamed Mokhtar Desouki; Anupma Nayak; Mathew Hanna; Souzan Sanati; Xuan Peng; Li Yan; Xiaoxian Li; Oluwole Fadare; Christine Ambrosone; Nashwan Jabbour; Carmelo Gaudioso
Journal:  Breast J       Date:  2019-10-06       Impact factor: 2.431

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.